Navigation Links
Shire plc: Change to Director's Details
Date:2/5/2009

PHILADELPHIA and DUBLIN, February 5 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Mr Matthew Emmens, non-executive Chairman of Shire, has been appointed President of Vertex Pharmaceuticals Incorporated with immediate effect and that Mr Emmens will in addition become Chairman and Chief Executive Officer of Vertex in May 2009 when the current Chief Executive Officer retires.

    This announcement is made pursuant to Listing Rule 9.6.14R.

    Tony Guthrie
    Deputy Company Secretary


    Notes to editors
    Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

    For further information please contact:

    Investor Relations
    Clea Rosenfeld (Rest of the World)
    +44-1256-894-160

    Eric Rojas (North America)
    +1-617-551-9715

    Media
    Matthew Cabrey (Specialty Pharma)
    +1-484-595-8248

    Jessica Cotrone (HGT)
    +1-617-613-4640


'/>"/>
SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
2. Shires New Product Portfolio Delivers Strong Quarterly Performance
3. Change of Name to Shire plc
4. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
5. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
6. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
7. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
8. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
9. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
10. Application for Listing of Shire Limited Ordinary Shares
11. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 According to ... by Products (Consumable, Instruments, Automated Cell Expansion System), ... Stem Cell Research, Cancer, and Cell-Based Research), End-users ... - Global Revenue, Trends, Growth, Share, Size and ... the global cell expansion market is expected to ...
(Date:12/5/2016)... CALGARY , Dec. 5, 2016 /PRNewswire/ - ... announced  that the independent Data and Safety Monitoring ... trial in high-risk cardiovascular disease (CVD) patients has ... that the study should continue as planned without ... and noted that no safety or efficacy concerns ...
(Date:12/5/2016)... 5, 2016  Eisai Inc. announced today final ... of rufinamide, which were presented at the 2016 ... held from December 2-6 in Houston, ... tolerability and cognitive data showed that patients who ... and tolerability profiles, cognitive development and behavior, compared ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
Breaking Biology News(10 mins):